Component

Aged garlic extract in the European 2020 coronary-calcium trial

Aged garlic extract in the European 2020 coronary-calcium trial. Interpret through the linked study species, preparation, exposure and measured endpoint.

2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What it acts on

  1. The European AGE trial reported lower coronary calcium-score progression than placebo over one year.

    Aged garlic extract in the European 2020 coronary-calcium trial → Coronary calcium-score progression in the aged garlic trial source_derived_draftungraded
    Experimental context and source evidence
    evidence_access
    Primary full text available; selected claim-relevant methods, results, tables/figures and limitations reviewed. Supplemental proteome and all secondary findings are not exhaustively extracted.
    experimental_contrast
    {"intervention": "Specified aged garlic extract", "comparator": "Placebo", "endpoint": "The European AGE trial reported lower coronary calcium-score progression than placebo over one year.", "effect_direction": "decrease", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
    experimental_model
    104 randomized, 93 analyzed; 2.4 g/day AGE; baseline-adjusted analyses of imaging progression.
    interpretation_status
    Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
    limitations
    Retrospective trial registration, baseline imbalances and manufacturer support; surrogate imaging outcome, not plaque reversal or fewer cardiovascular events.
    plain_language
    The European AGE trial reported lower coronary calcium-score progression than placebo over one year.
    primary_references
    The effect of aged garlic extract on the atherosclerotic process - a randomized double-blind placebo-controlled trial. | 2020 | DOI 10.1186/s12906-020-02932-5 | PMID 32349742 | https://pubmed.ncbi.nlm.nih.gov/32349742/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC7191741/ | https://doi.org/10.1186/s12906-020-02932-5
    source_locator
    Reviewed reference lines 93-93; exact primary location described in quoted passage where extracted.

    Allicin: detailed mechanisms of action (reviewed 5 October 2026) · lines 93–93

    Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · 104 randomized, 93 analyzed; 2.4 g/day AGE; baseline-adjusted analyses of imaging progression. · source_derived_draft · unverified_draft

    **Coronary imaging.** A European trial randomized 104 participants to 2.4 g/day aged garlic extract or placebo for one year; ninety-three were analyzed. It reported lower coronary-calcium progression with the extract. It was retrospectively registered and received manufacturer funding and product support alongside other funding. Coronary calcium progression is an imaging outcome, not proof of plaque reversal, fewer infarctions, or allicin target engagement. It must remain distinct from low-attenuation plaque and total plaque-volume measurements. [Wlosinska 2020](https://pmc.ncbi.nlm.nih.gov/articles/PMC7191741/)
    Complete structured claim and evidence

What acts on it

  1. The aged-garlic-wlosinska-2020 study is a preparation-specific translation comparison; its outcomes are not assigned to purified allicin.

    Allicin → Aged garlic extract in the European 2020 coronary-calcium trial source_derived_draftungraded
    Experimental context and source evidence
    evidence_access
    Primary full text available; selected claim-relevant methods, results, tables/figures and limitations reviewed. Supplemental proteome and all secondary findings are not exhaustively extracted.
    experimental_model
    Editorial study-scope relationship, not experimental causation or chemical composition.
    interpretation_status
    Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
    limitations
    Unsigned navigation only. Does not assert allicin content, metabolic conversion, causation or intervention equivalence.
    plain_language
    The aged-garlic-wlosinska-2020 study is a preparation-specific translation comparison; its outcomes are not assigned to purified allicin.
    primary_references
    The effect of aged garlic extract on the atherosclerotic process - a randomized double-blind placebo-controlled trial. | 2020 | DOI 10.1186/s12906-020-02932-5 | PMID 32349742 | https://pubmed.ncbi.nlm.nih.gov/32349742/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC7191741/ | https://doi.org/10.1186/s12906-020-02932-5
    source_locator
    Reviewed reference lines 93-93; exact primary location described in quoted passage where extracted.

    Allicin: detailed mechanisms of action (reviewed 5 October 2026) · lines 93–93

    Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Editorial study-scope relationship, not experimental causation or chemical composition. · source_derived_draft · unverified_draft

    **Coronary imaging.** A European trial randomized 104 participants to 2.4 g/day aged garlic extract or placebo for one year; ninety-three were analyzed. It reported lower coronary-calcium progression with the extract. It was retrospectively registered and received manufacturer funding and product support alongside other funding. Coronary calcium progression is an imaging outcome, not proof of plaque reversal, fewer infarctions, or allicin target engagement. It must remain distinct from low-attenuation plaque and total plaque-volume measurements. [Wlosinska 2020](https://pmc.ncbi.nlm.nih.gov/articles/PMC7191741/)
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.